Related Experiment Videos
Malignant solid tumors associated with congenital immunodeficiency disorders
Ali Varan1, M Büyükpamukçu, Fügen Ersoy
1Department of Pediatric Oncology, Hacettepe University, Institute of Oncology, Ankara, Turkey. avaran@hacettepe.edu.tr
Pediatric Hematology and Oncology
|June 19, 2004
Summary
Patients with immunodeficiency syndromes face poor survival rates when developing malignant solid tumors. Non-Hodgkin lymphoma showed worse outcomes than Hodgkin disease in this patient group.
Area of Science:
- Immunology
- Oncology
- Genetics
Background:
- Immunodeficiency syndromes are associated with an increased risk of malignancies.
- Solid tumors in patients with primary immunodeficiency disorders are rare but aggressive.
Purpose of the Study:
- To evaluate survival rates and prognosis of malignant solid tumors in patients with immunodeficiency syndromes.
- To examine the relationship between specific immunodeficiency diseases and cancer types.
Main Methods:
- Retrospective analysis of 22 patients diagnosed with malignant solid tumors and immunodeficiency syndromes between 1972 and 2003.
- Categorization of patients by immunodeficiency type and cancer histology.
- Calculation of overall survival rates for different cancer types and immunodeficiency disorders.
Main Results:
- The overall survival rate for the entire cohort was 24%.
- Non-Hodgkin lymphoma (17% survival) and Hodgkin disease (44% survival) were the most common malignancies.
- Ataxia-telangiectasia was the most frequent immunodeficiency syndrome (68%), with a 20% survival rate in affected patients.
- Survival rates for colon carcinoma and brain stem glioma were 0%.
Conclusions:
- Malignant solid tumors in patients with immunodeficiency syndromes have a very poor prognosis.
- Non-Hodgkin lymphoma demonstrated a poorer survival rate compared to Hodgkin disease in this population.
- Ataxia-telangiectasia is a significant risk factor for developing specific solid tumors within immunodeficiency syndromes.